MAPT and Alzheimer disease: Two other clinical trials of lecanemab are ongoing: a large Phase 3 trial (AHEAD 3-45) in people who are cognitively normal but have elevated brain amyloid, and the first DIAN-TU prevention study of concurrent therapies targeting amyloid and tau in people with familial AD mutations, pairing lecanemab with an anti-tau humanized mAb known as E2814 (Eisai) (68).